First Commonwealth Finl (NYSE:FCF) reported quarterly earnings of $0.39 per share which missed the analyst consensus estimate of $0.43 by 9.3 percent. This is a 5.41 percent increase over earnings of $0.37 per share from the same period last year.
Earlier, Sanofi Announced FDA Approved Once-Weekly Altuviiio, New Class of Factor VIII Therapy For Hemophilia A That Offers Significant Bleed Protection
The U.S. Food and Drug Administration (FDA) has approved ALTUVIIIO™ [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl], previously referred to as efanesoctocog alfa, a first-in-class, high-sustained factor VIII replacement therapy.The U.S.
